290 related articles for article (PubMed ID: 16400019)
1. Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to leishmania donovani infection but develop severe liver immunopathology.
Rosas LE; Satoskar AA; Roth KM; Keiser TL; Barbi J; Hunter C; de Sauvage FJ; Satoskar AR
Am J Pathol; 2006 Jan; 168(1):158-69. PubMed ID: 16400019
[TBL] [Abstract][Full Text] [Related]
2. Essential role for IL-27 receptor signaling in prevention of Th1-mediated immunopathology during malaria infection.
Findlay EG; Greig R; Stumhofer JS; Hafalla JC; de Souza JB; Saris CJ; Hunter CA; Riley EM; Couper KN
J Immunol; 2010 Aug; 185(4):2482-92. PubMed ID: 20631310
[TBL] [Abstract][Full Text] [Related]
3. IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology.
Satoskar AR; Rodig S; Telford SR; Satoskar AA; Ghosh SK; von Lichtenberg F; David JR
Eur J Immunol; 2000 Mar; 30(3):834-9. PubMed ID: 10741399
[TBL] [Abstract][Full Text] [Related]
4. Lack of CXCR3 delays the development of hepatic inflammation but does not impair resistance to Leishmania donovani.
Barbi J; Oghumu S; Rosas LE; Carlson T; Lu B; Gerard C; Lezama-Davila CM; Satoskar AR
J Infect Dis; 2007 Jun; 195(11):1713-7. PubMed ID: 17471442
[TBL] [Abstract][Full Text] [Related]
5. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis.
Kaye PM; Curry AJ; Blackwell JM
J Immunol; 1991 Apr; 146(8):2763-70. PubMed ID: 1901883
[TBL] [Abstract][Full Text] [Related]
6. Defects in the generation of IFN-gamma are overcome to control infection with Leishmania donovani in CC chemokine receptor (CCR) 5-, macrophage inflammatory protein-1 alpha-, or CCR2-deficient mice.
Sato N; Kuziel WA; Melby PC; Reddick RL; Kostecki V; Zhao W; Maeda N; Ahuja SK; Ahuja SS
J Immunol; 1999 Nov; 163(10):5519-25. PubMed ID: 10553079
[TBL] [Abstract][Full Text] [Related]
7. Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice.
Dey R; Majumder N; Bhattacharyya Majumdar S; Bhattacharjee S; Banerjee S; Roy S; Majumdar S
Scand J Immunol; 2007 Dec; 66(6):671-83. PubMed ID: 18021365
[TBL] [Abstract][Full Text] [Related]
8. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
Tripathi P; Gupta SK; Sinha S; Sundar S; Dube A; Naik S
Scand J Immunol; 2008 Nov; 68(5):492-501. PubMed ID: 18803606
[TBL] [Abstract][Full Text] [Related]
10. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice.
Lehmann J; Enssle KH; Lehmann I; Emmendörfer A; Lohmann-Matthes ML
J Interferon Cytokine Res; 2000 Jan; 20(1):63-77. PubMed ID: 10670653
[TBL] [Abstract][Full Text] [Related]
11. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
12. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response.
Mattner F; Magram J; Ferrante J; Launois P; Di Padova K; Behin R; Gately MK; Louis JA; Alber G
Eur J Immunol; 1996 Jul; 26(7):1553-9. PubMed ID: 8766560
[TBL] [Abstract][Full Text] [Related]
13. The IL-33/ST2 axis is associated with human visceral leishmaniasis and suppresses Th1 responses in the livers of BALB/c mice infected with Leishmania donovani.
Rostan O; Gangneux JP; Piquet-Pellorce C; Manuel C; McKenzie AN; Guiguen C; Samson M; Robert-Gangneux F
mBio; 2013 Sep; 4(5):e00383-13. PubMed ID: 24045639
[TBL] [Abstract][Full Text] [Related]
14. Leishmania donovani: role of CD2 on CD4+ T-cell function in Visceral Leishmaniasis.
Bimal S; Singh SK; Sinha S; Pandey K; Sinha PK; Ranjan A; Bhattacharya SK; Das P
Exp Parasitol; 2008 Feb; 118(2):238-46. PubMed ID: 17904553
[TBL] [Abstract][Full Text] [Related]
15. Parasite accessory cell interactions in murine leishmaniasis. I. Evasion and stimulus-dependent suppression of the macrophage interleukin 1 response by Leishmania donovani.
Reiner NE
J Immunol; 1987 Mar; 138(6):1919-25. PubMed ID: 3493291
[TBL] [Abstract][Full Text] [Related]
16. The role of mannose receptor during experimental leishmaniasis.
Akilov OE; Kasuboski RE; Carter CR; McDowell MA
J Leukoc Biol; 2007 May; 81(5):1188-96. PubMed ID: 17261547
[TBL] [Abstract][Full Text] [Related]
17. Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis.
Narayan S; Bimal S; Singh SK; Gupta AK; Singh VP; Sinha PK; Das P
Exp Parasitol; 2009 Jan; 121(1):69-75. PubMed ID: 18948098
[TBL] [Abstract][Full Text] [Related]
18. Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma.
Murray HW; Stern JJ; Welte K; Rubin BY; Carriero SM; Nathan CF
J Immunol; 1987 Apr; 138(7):2290-7. PubMed ID: 3104456
[TBL] [Abstract][Full Text] [Related]
19. CD95 is required for the early control of parasite burden in the liver of Leishmania donovani-infected mice.
Alexander CE; Kaye PM; Engwerda CR
Eur J Immunol; 2001 Apr; 31(4):1199-210. PubMed ID: 11298345
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic glucocorticoid-induced TNF receptor-mediated amplification of CD4+ T cell responses enhances antiparasitic immunity.
Haque A; Stanley AC; Amante FH; Rivera Fde L; Zhou Y; Kuns RD; Yardley V; Sakaguchi S; Hill GR; Engwerda CR
J Immunol; 2010 Mar; 184(5):2583-92. PubMed ID: 20139272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
